This glucagon-like peptide-1 (GLP-1) receptor agonist is marketed under the brand names Ozempic, Wegovy, and Rybelsus, each FDA-approved for specific indications
The product appears as a clear, colorless solution with no visible particles
Lilly, in turn, is using its vial rollout and legal action to provide safer, legitimate alternatives to compounding pharmacies
Its unique dual action as a GIP and GLP-1 receptor agonist makes it stand out from other weight management agents, offering enhanced efficacy in regulating blood sugar and supporting fat loss
Clinical trials suggest Mounjaro (tirzepatide) may lead to slightly greater weight loss than Wegovy (semaglutide), largely because it works on two hormone pathways rather than one